Recent

% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

  • druggy62 druggy62 Feb 8, 2013 5:18 PM Flag

    Valuation Comparisons

    Let's use Titan for example:

    TTNP:
    Market size for product: $1.5 billion
    Estimated peak sales: $500 million
    Market cap: $160 million

    KERX:
    Market size for product: $1.5 billion
    Estimated peak sales: $600 million
    Market cap: $480 million

    TTNP already has a PDUFA date and a partner.
    If KERX is so undervalued, than TTNP is triply undervalued.
    Or KERX is grossly overvalued.
    Which is it?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ok Einstein let me explain to you why that OTC board junk you're pumping is worth so little...
      the peak sales for Probuphine is in 300M-500M and all TTNP will get out of this is double digit royalty, you know what that means?...10%-12% most likely..now do the math..in the best case scenario Titan will have just 30M to 50M annual income from this drug...I say 160M cap is pretty generous already..so, get lost

      • 1 Reply to a_gasparyan
      • Who the F gives what exchange a company is listed on in a valuation comparison?
        10% to 12%, try 20% to 25%.

        Hey genius, will KERX go it alone against Sanofi and Shire?
        When they partner, don't you think that they will get a royalty too?

        OK, so lets use your 10% to 12% royalty for KERX.
        What would their income be? $60M to $70M?
        How does your $480M market cap look then?

        We don't have to use TTNP in the comparison.
        Wanna try another? POZN, DEPO, PATH?

        So you take a hike, obnoxious twit.
        You think you know it all, but you have a lot to learn.

 
KERX
6.42+0.22(+3.55%)Aug 28 4:00 PMEDT